IRWD Stock: Ironwood Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live irwd stock price $3.54, comprehensive Ironwood Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time irwd stock data and investment insights.
Loading chart...
Company Overview
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Company Information
- CEO
- Thomas A. McCourt
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 253
Contact Information
- Address
- 100 Summer Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 19.7)
✓ Lower volatility stock (Beta: 0.18) may provide portfolio stability
Business Model & Strategy
Ironwood Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Thomas A. McCourt, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - Specialty & Generic model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Ironwood Pharmaceuticals, Inc. competes in the Drug Manufacturers - Specialty & Generic within the broader Healthcare. With 575.9 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Ironwood Pharmaceuticals, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Ironwood Pharmaceuticals, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Ironwood Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Ironwood Pharmaceuticals, Inc.
- ⚠Investors should consider how Ironwood Pharmaceuticals, Inc. fits within their overall portfolio allocation
Market Cap
575.88M
P/E Ratio
19.67
Beta
0.18
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 575.88M market capitalization
- Trading Volume: 3.95M shares traded today
- Price Range: 52-week range of $0.53 - $5.13
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. (IRWD) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 575.88M, the company represents a significant player in its market. The stock is currently trading at $3.54 with a negativedaily change of 1.39%.
The company's 253 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 19.67, beta of 0.18, and 52-week price range from $0.53 to $5.13when evaluating investment opportunities.
Why Invest in Ironwood Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Thomas A. McCourt
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.